Liquid biopsy analysis detects cell-free DNA (cfDNA) released into the bloodstream by necrotic and apoptotic cells and thus offers an optimal alternative when tumor tissue is unavailable. However, only a fraction of circulating DNA originates from the tumor itself. Therefore, highly sensitive methods are required to detect these minimal ctDNA concentrations.
We at CeGaT established our CancerDetect® panel using duplex UMI-based technology, which detects sequence variants in actionable, most prevalent hotspots. Moreover, due to non-invasive and repeatable sampling, CancerDetect® represents a great approach to monitoring. By very sensitive detection of tumor-specific biomarkers, the analysis of ctDNA can be used as a surrogate marker for treatment response during medical follow-up.
Are you insured in Germany? Our colleagues at the Zentrum für Humangenetik Tübingen will gladly support you!